Analysis of the Current Status of CRS Due to Pediatric ALL Treated with CAR-T Therapy
DOI:
https://doi.org/10.61173/tz65av12Keywords:
CAR-T cell therapy, pediatric ALL, CRS, immune-related adverse effects, tumor immunotherapyAbstract
Chimeric antigen receptor (CAR)-T therapy has been a popular treatment for tumors in recent years, and it has good efficacy for pediatric acute lymphoblastic leukemia (ALL), especially B-lymphoblastic ALL. Generally, CAR-T therapy affects the tumor immune microenvironment and activates the immune response, so it may lead to the occurrence of inflammation and some other adverse effects, most of which are self-limiting symptoms. However, a small number of children will develop severe cytokine release syndrome (CRS), which may be life-threatening in severe cases. Currently, the main means of treating or alleviating CRS is the application of monoclonal antibodies, glucocorticosteroids, boosting drugs, etc. Although these drugs can relieve symptoms, further effects need to be further discussed. The mechanism of CAR-T causing ALL is described in this paper, and the mechanism, advantages and disadvantages of various drugs, and their impact on tumor treatment are compared to analyze the better measures to deal with CRS, so as to provide ideas for further clinical practice.
References
[1] CAPRIA S,MOLICA M,MOHAMED S,et al.A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia[J].Expert Rev Hematol,2020,13(7):755-769
[2] SUN Huijing,HUANG Shuqi,ZHOU Shuguang et al. Clinical characteristics and risk factors of infection during chemotherapy for acute lymphoblastic leukemia in children[J]. Chinese Journal of Clinical Pharmacy,2022,31(07):481-485.
[3] Xie WQ. Clinical efficacy analysis of 44 cases of unrelated hematopoietic stem cell transplantation for acute lymphoblastic leukemia[D]. Guangxi Medical University,2019.
[4] GUO Xin, HAO Lichang, LIANG Ji. Research progress in genetic diagnosis and treatment of acute lymphoblastic leukemia in children and adolescents[J]. Journal of Jilin Medical College,2022,43(06):458-461.
[5] Demidowicz E, Pogorzała M, Łęcka M, et al. Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. Anticancer Res. 2019;39(9). 5203-5207.
[6] Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664-679.
[7] Benmebarek M-R, Karches CH, Cadilha BL, et al. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences. 2019; 20(6):1283.
[8] Han D, Xu Z, Zhuang Y, et al. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer. 2021 Jan 1;12(2):326-334.
[9] Xu X, Huang S, Xiao X, et al. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Front Immunol. 2021;11:569117.
[10] Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/ relapsed B-cell malignancies. blood. 2020;135(1):17-27.
[11] Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959 -70.
[12] Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11 (8):633-52.
[13] Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9:15.
[14] Michael D. Jain, Melody Smith, Nirali N. Shah; How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 2023; 141 (20): 2430- 2442.
[15] Brudno JN,Kochenderfer JN.Recent advance in CAR T-cell toxicity:mechanisms,manifestations and management[J].Blood Rev,2019,34:45-55.
[16] Adkins S. CAR T-Cell Therapy: Adverse Events and Management. J Adv Pract Oncol. 2019 May-Jun;10(Suppl 3):21- 28.
[17] Kauer J, Hörner S, Osburg L, et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020 May;8(1):e000621.
[18] Brandl C, Haas C, d’Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific singlechain antibody construct. Cancer Immunol Immunother
[19] Gazeau N, Liang EC, Wu QV, et al. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 Jul;29(7):430-437.
[20] Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323-335
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
